Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma

Head and Neck

Volumn 32, Issue 6, 2010, Pages 689-698

  Vaisman, Alon ^a   Orlov, Steven ^a   Yip, Jonathan ^a   Hu, Cindy ^a   Lim, Terence ^a   Dowar, Mark ^a   Freeman, Jeremy L ^a   Walfish, Paul G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clinical research; Radiology radiation treatment; Thyroglobulin; Thyroid cancer clinical; TSH

Indexed keywords

RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROGLOBULIN ANTIBODY;

ABLATION THERAPY; ADULT; AGED; ARTICLE; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; CLINICAL RESEARCH; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; OUTCOME ASSESSMENT; PATIENT SELECTION; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURGICAL TECHNIQUE; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; ALGORITHMS; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IODINE RADIOISOTOPES; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PATIENT SELECTION; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 77952747980     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21371     Document Type: Article

References (45)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-2167.
2. Sawka AM, Goldstein DP, Thabane L, et al. Basis for physician recommendations for adjuvant radioiodine therapy in early-stage thyroid carcinoma: principal findings of the Canadian-American thyroid cancer survey. Endocr Pract 2008;14:175-184.
3. Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol 2006;94:692-700.
4. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668-3676. (Pubitemid 39089119)
5. Pacini F, Schlumberger M, Harmer C, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 2005;153:651-659. (Pubitemid 41672411)
6. Brierley J, Tsang R, Panzarella T, Bana N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf) 2005;63: 418-427. (Pubitemid 41442336)
7. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:1229-1242. (Pubitemid 46080167)
8. Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr Pract 2007;13:498-512.
9. Solans R, Bosch JA, Galofré P, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001;42:738-743. (Pubitemid 32453462)
10. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-142.
11. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803. (Pubitemid 43997716)
12. British Thyroid Association RCoP. Guidelines for the management of thyroid cancer. 2nd edition. London: Royal College of Physicians; 2007.
13. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050-1057; discussion 1057-1058.
14. Orlov S, Orlov D, Shaytzag M, et al. Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. Head Neck 2009;31:782-788.
15. Black EG, Cassoni A, Gimlette TM, et al. Serum thyroglobulin in thyroid cancer. Lancet 1981;2:443-445.
16. Blahd WH, Drickman MV, Porter CW, Hill VA, Baumgartner WA. Serum thyroglobulin, a monitor of differentiated thyroid carcinoma in patients receiving thyroid hormone suppression therapy: concise communication. J Nucl Med 1984;25:673-676.
17. Eustatia-Rutten CF, Smit JW, Romijn JA, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004;61:61-74. (Pubitemid 38951647)
18. Heemstra KA, Liu YY, Stokkel M, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2007;66:58-64. (Pubitemid 44952495)
19. Kim TY, Kim WB, Kim ES, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005;90:1440-1445.
20. Lin JD, Huang MJ, Hsu BR, et al. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. J Surg Oncol 2002;80:45-51. (Pubitemid 34477735)
21. Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 1999;26:1448-1452. (Pubitemid 29515606)
22. Sawka AM, Orlov S, Gelberg J, et al. Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma. Head Neck 2008; 30:693-700. (Pubitemid 351913843)
23. Toubeau M, Touzery C, Arveux P, et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004;45:988-994.
24. Bernier MO, Morel O, Rodien P, et al. Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2005;32:1418-1421. (Pubitemid 41746846)
25. Giovanella L, Ceriani L, Suriano S, Ghelfo A, Maffioli M. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2008;69:659-663.
26. Hall FT, Beasley NJ, Eski SJ, Witterick IJ, Walfish PG, Freeman JL. Predictive value of serum thyroglobulin after surgery for thyroid carcinoma. Laryngoscope 2003;113:77-81.
27. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005;90:5566-5575. (Pubitemid 41415459)
28. Golger A, Fridman TR, Eski S, Witterick IJ, Freeman JL, Walfish PG. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma. J Endocrinol Invest 2003;26:1023-1031. (Pubitemid 38049156)
29. Toft A, Beckett G. Use of recombinant thyrotropin. Lancet 2002;359:1874-1875.
30. Yip J, Hu C, Orlov S, et al. Serial stimulated thyroglobulin measurements in low-risk well-differentiated thyroid carcinoma patients not receiving radioactive remnant ablation. Program and abstracts 80th Annual Meeting of the American Thyroid Association, Palm Beach, Florida. September 23-27, 2009. Thyroid 2009.
31. Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997;7:265-271. (Pubitemid 27190594)
32. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-1463.
33. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26:879-885.
34. Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008;37:457-480, x.
35. Park EK, Chung JK, Lim IH, et al. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging 2009;36:172-179.
36. Mertens IJ, De Klerk JM, Zelissen PM, et al. Undetectable serum thyroglobulin in a patient with metastatic follicular thyroid cancer. Clin Nucl Med 1999; 24:346-349.
37. Bonnet S, Hartl D, Leboulleux S, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 2009;94:1162-1167.
38. Silberstein EB. Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. J Nucl Med 2008;49:546-549.
39. Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 2005;117:281-288. (Pubitemid 41377449)
40. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638-1644. (Pubitemid 37464133)
41. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin EndocrinolMetab 2008;93:504-515. (Pubitemid 351240823)
42. Pace-Asciak PZ, Payne RJ, Eski SJ, Walfish P, Damani M, Freeman JL. Cost savings of patients with a MACIS score lower than 6 when radioactive iodine is not given. Arch Otolaryngol Head Neck Surg 2007;133:870-873. (Pubitemid 47437273)
43. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104:947-953. (Pubitemid 19011971)
44. Iervasi A, Iervasi G, Ferdeghini M, et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf) 2007;67:434-441. (Pubitemid 47283844)
45. Smallridge RC, Meek SE, Morgan MA, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007;92:82-87.